Search Results
Your search for ,HIS matches 4421 pages
Showing 101 - 150ASTRO Names New Chief Executive Officer
The American Society for Radiation Oncology (ASTRO) announced that following a nationwide search, Vivek S. Kavadi, MD, MBA, FASTRO, will become Chief Executive Officer of the Society, effective November 1, 2024. Dr. Kavadi will succeed Laura Thevenot, who had already announced her intent to retire...
Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center
Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, has been named the Executive Director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center and UNC System Chief of Oncology Services, effective October 1, announced the Dean of the UNC School of Medicine...
V. Craig Jordan, PhD, a Founding Father of Targeted Therapy in Cancer, Dies at Age 76
Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact the field for generations to come, died on June 9, according to a news release from The University of Texas MD Anderson Cancer...
How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life
Several years ago, a visit to the National Air and Space Museum in Washington, DC, so fascinated and inspired Mace L. Rothenberg, MD, FASCO, about the history of flight, he wondered why there was not a similar museum showcasing the past and present achievements in science and medicine. The result...
Dennis J. Slamon, MD, PhD, Awarded 2024 Szent-Györgyi Prize for Progress in Cancer Research
The National Foundation for Cancer Research (NFCR) announced that the blue-ribbon selection committee, composed of world-renowned research leaders and visionaries, has awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research to Dennis J. Slamon, MD, PhD, of UCLA Health, for his...
Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010). Background Circulating...
A Father’s Advice Plus a Desire to Help Spur a Career in Oncology and a Leadership Role in African Cancer Care
Miriam Mutebi, MD, MSc, FACS, was born and reared in the outskirts of Nairobi, Kenya. “The suburb I grew up in (Langata), has seen a lot of development over the past couple of decades. When I was a child, it was a smaller community, where you would go and play at somebody else’s house and have...
For an International Expert in Gynecologic Cancer, Being Reared by Educators Who Stressed Knowledge and Service Was Key
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to her current position as Founding Dean and Chief Executive Officer of the Alice L. Walton School of Medicine, Bentonville, Arkansas. Raised by...
Motivated by His Mother’s Brain Cancer and His Own Life-Threatening Disease, a Young Physician Works to ‘Pay Back the Universe’
Like many young boys, David Fajgenbaum, MD, MBA, MSc, loved sports and dreamed about playing college football. He attained that dream, but along the way, family tragedy and a personal battle with a life-threatening disease reshaped his worldview and accelerated his ambitions as a...
Immigrant Reared During the Lebanese Civil War by Parents Who Valued Education Becomes a Leader in Genitourinary Oncology
Genitourinary cancer expert Toni K. Choueiri, MD, FASCO, was born in 1975 in Beirut, Lebanon, the year a devastating civil war erupted, lasted for 15 years, and cost the lives of some 150,000 individuals and also led to the exodus of almost 1 million people from Lebanon. “People with the financial...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
The National Cancer Act of 1971 Inspired a Career in Service to and Advocacy for Patients With Cancer
ASCO President for the 2024–2025 term, Robin Zon, MD, FACP, FASCO, was born and reared in Cheektowaga, a town in the western part of New York. “Cheektowaga is the Native American name for ‘land of the crabapple tree.’ Western New York was first settled by one of seven tribes belonging to the...
A Mother’s Encouragement and a Husband-Wife Doctor Team Set the Stage for a Career in Hematologic Oncology
Lymphoma expert Jane N. Winter, MD, grew up on the south shore of Long Island in New York. “My dad sold cars in my great uncle’s dealership after a failed foray into business after World War II. My mom graduated high school at 16 to go to work to help support her family. When my younger brother...
A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference
ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...
NCCN Appoints Chair, Vice-Chair of Board of Directors
The National Comprehensive Cancer Network (NCCN®) has announced the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022. “The exemplary leadership from our Board...
A Look Back on an Impactful and Inspiring Presidential Year
Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...
Partnering With Patients Is Integral for a Good Outcome
About 3 years ago, I woke up from a sound sleep and was having a hard time breathing. It felt like someone was sitting on my neck, constricting my airways. I could feel prominent swelling in my lymph nodes along my neck and clavicle, and I was scared. A trip to the emergency room proved fruitless, ...
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Joins Perthera as Chief Medical Officer
Perthera, an industry leader in precision oncology decision support, recently announced that Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, joined Perthera as Chief Medical Officer. Dr. Raghavan is founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland...
Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer
For breast cancer that is estrogen receptor–positive, CDK4/6 inhibitors, given with endocrine therapy, have become the standard of care, especially in metastatic disease. However, resistance to both endocrine therapies and CDK4/6 inhibitors is common, and new approaches are needed to counteract...
CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma
Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...
Onychopapilloma May Be Linked to BAP1 Tumor Predisposition Syndrome
Researchers have discovered that the presence of a benign nail condition known as onychopapilloma may lead to the diagnosis of BAP1 tumor predisposition syndrome, according to a recent study presented by Lebensohn et al at the Society for Investigative Dermatology 2024 Annual Meeting and...
NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...
Providing Culturally Sensitive Palliative Care to Children With Cancer
In the fall of 2023, Justin Baker, MD, took on the role of Chief of the Division of Quality of Life and Pediatric Palliative Care and Director of the Quality of Life for All Program, Stanford Medicine Children’s Health, Stanford, California. He formerly worked at St. Jude Children’s Research...
Early Relapsed/Refractory DLBCL
This is Part 1 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the treatment of early...
A Delay in Diagnosis Led to Advanced Prostate Cancer
Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...
Bishoy Faltas, MD, Named Chief Research Officer of the Englander Institute for Precision Medicine at Weill Cornell Medicine
Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD, has been named Chief Research Officer of EIPM effective immediately. EIPM is a large multidisciplinary institute that uses...
Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer
Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...
Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer
Saruparib, a first-in-class PARP1-selective inhibitor, was reported to have favorable safety and anticancer activity in heavily pretreated patients with breast cancer harboring homologous recombination–repair (HRR) mutations, according to the results of the phase I/II PETRA study presented at the...
Expert Point of View: Glenn J. Hanna, MD
Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program), medical oncologist at the Center for Head & Neck Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School, Boston, was interviewed for his...
Adagrasib Plus Cetuximab: Potential Option for KRAS G12C–Mutated Colorectal Cancer
Although KRAS was once considered an untargetable mutation, KRAS inhibitors are now approved for the treatment of KRAS-mutated non–small cell lung cancer (NSCLC) and are emerging as a potential option for the treatment of KRAS G12C–mutated colorectal cancer in combination with other therapies....
Third-Line Treatment of Relapsed/Refractory Follicular Lymphoma in a Patient With High-Risk Features
This is Part 3 of Treatment Options for Relapsed/Refractory Follicular Lymphoma: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew M. Evens, L. Elizabeth Budde, and Carla Casulo discuss the third-line...
Second-Line Treatment of Relapsed Follicular Lymphoma in a Patient With Comorbidities
This is Part 1 of Treatment Options for Relapsed/Refractory Follicular Lymphoma: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew M. Evens, L. Elizabeth Budde, and Carla Casulo discuss the second-line...
Refractory RCC After Disease Progression on Adjuvant IO Therapy
This is Part 2 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of refractory...
Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations
Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...
ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...
Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer
The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1...
Feasibility of Ending Specialist Follow-up in Patients With Low-Risk CLL
A study published by Brieghel et al in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, ...
Can Artificial Intelligence Predict Treatment Response and Outcomes in Breast Cancer?
Artificial intelligence (AI)—computational analytics with routine imaging via radiology or pathology—can advance precision medicine in breast cancer, specifically by predicting response to therapy and calculating prognosis, according to a pioneer in the field, Anant Madabhushi, PhD, of Emory...
Managing Accelerated- and Blast-Phase Myeloproliferative Neoplasms
This is Part 3 of Addressing Unmet Needs in Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. John Mascarenhas, Gabriela Hobbs, and Abdulraheem Yacoub discuss the management of accelerated- and blast-phase...
Managing Treatment-Emergent Anemia in a Patient With Myelofibrosis
This is Part 1 of Addressing Unmet Needs in Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. John Mascarenhas, Gabriela Hobbs, and Abdulraheem Yacoub discuss the management of treatment-emergent anemia in a...
ASCO Congratulates 2024 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting. The 2024 Special Award Recipients...
A Clinical Trial for Bladder Cancer Gave Me Back My Life
About 8 years ago, I was just a few years into menopause when I noticed blood in my urine. It wasn’t accompanied by pain, frequent urination, or any other troubling symptoms, so initially I wasn’t too concerned. But when I started passing pieces of tissue, I became alarmed and made an appointment...
Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status
The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...
W. Kimryn Rathmell, MD, PhD, Selected as 17th Director of the NCI
W. Kimryn Rathmell, MD, PhD, took the helm as the 17th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), on December 18, 2023. A renowned kidney cancer expert and influential leader in cancer research and patient care, Dr. Rathmell was selected by...
Cancer Care Providers Urge President Biden to Make Health Care a State of the Union Priority
In a news release issued by ASCO earlier this month, the society reported that The Association for Clinical Oncology (ASCO) was calling on President Biden to continue to prioritize access to high-quality, equitable cancer care in his State of the Union address. Specifically, the cancer care...
Strategies for Cardiovascular Risk Mitigation and Monitoring in Patients With CLL
With a 5-year overall survival of close to 90% in chronic lymphocytic leukemia (CLL), there have been large treatment shifts over the past decade in this disease, which now includes “more disciplines than it did before,” commented medical oncologist Danielle Shafer, DO, of Inova Schar Cancer...
Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer
Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...
From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research
Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...
Risk Score to Assess Cardiovascular Complications in Hematopoietic Stem Cell Transplant Recipients
A novel tool may help predict the risk of complications following hematopoietic stem cell transplantation and guide the pretransplant process, according to new Scientific Statement published by Hayek et al in Circulation. The findings may also illuminate the contemporary prevalence of...
